Immunovaccine appoints new CEO
Mansour led the development of Immunovaccine's DepoVax platform, which has been used to create cancer immunotherapies and infectious disease vaccines, including a vaccine candidate against the bioterrorism agent anthrax.
Albert Scardino, who served as the executive chairman since 2013, will return to his role as non-executive chairman of the company.
"During his 13 years at Immunovaccine, Marc has contributed to all aspects of our development, from cutting-edge scientific research to day-to-day corporate operations," Scardino said. "No individual has a better understanding of where Immunovaccine has been or what it will take to advance the company to the next phase of its evolution."
In addition to developing the DepoVax platform, Mansour also helped to develop Immunovaccine's lead therapeutic cancer vaccine DPX-Survivac. Immunovaccine presented positive results earlier this month from a Phase I/Ib clinical study of DPX-Survivac that demonstrated clinical activity for the cancer vaccine.
"This is an exciting time for Immunovaccine and the broader cancer immunotherapy field," Mansour said. "Our announcement of the DPX-Survivac data at the annual (American Society of Clinical Oncology) conference has resulted in a significant amount of interest from key opinion leaders for further investigation of the cancer vaccine."
Mansour joined Immunovaccine in 2001 and has served as the company's chief operating officer and its chief science officer. Mansour is also a member of Immunovaccine's board of directors.